• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Pilot Study of Ketamine vs ECT for Major Depression

Pilot Study of Ketamine vs ECT for Major Depression

September 10, 2021
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Kheirabadi D et al, J Clin Psychopharm 2020;40(6):588–593

STUDY TYPE: Randomized controlled trial

Electroconvulsive therapy (ECT) has long been the gold standard for severe or treatment-refractory depression (TRD). However, it has two major drawbacks: it involves anesthesia and it may be associated with memory impairment. Ketamine has emerged as a possible alternative to ECT both for TRD and for acute suicidal ideation. Given ketamine’s advantage of working quickly, it is of great interest to know how these two very different treatments compare with each other.

In this study, investigators recruited 39 patients with severe depression, TRD, or acute suicidal ideation who were referred for ECT. These patients were then randomized to receive either ECT (n = 12), oral R-ketamine (n = 12), or IM ketamine (n = 15). All three treatments were offered for 6–9 sessions.

Depression scores improved over the course of three weeks in all three groups by about 40%–50% on the Hamilton Depression Rating Scale without significant differences between the groups. Several other differences did emerge, however: 1) Scores on suicidality ratings dropped significantly faster in patients receiving both versions of ketamine—as early as day 1—and remained lower through week 2; 2) The benefits of ECT and ketamine were apparent even one month post-treatment, though ECT appeared to display gains that were enduring yet not statistically significant; 3) Overall, patients receiving ketamine reported significantly higher levels of satisfaction, while patients receiving ECT were more likely to report significantly more cognitive complaints (58% of patients) one month post-treatment.

Ketamine is available in three forms: S-ketamine, R-ketamine, and ketamine (a 50/50 mixture of the two isomers). This study, which took place in Iran, used oral R-ketamine. In the US, intranasal S-ketamine (esketamine) is FDA approved for depression treatment as Spravato. The R- and S-isomers are not interchangable, and there is some evidence that the R-isomer may be even more effective than S-ketamine. The other ketamine arm in this study is identical to the racemic mixture of R- and S-ketamine that is used off-label for depression, except that it was delivered IM, whereas IV is the typical route in the US. Thus, we can’t be sure that these results would be the same for the kinds of ketamine used in the US.

TCPR’s Take
Given their small sample sizes, pilot studies should always be taken with a grain of salt. Nevertheless, these results are in line with prior research. Ketamine works more quickly than ECT especially for suicidal ideation and appears to be better tolerated, though ECT’s benefits may be more enduring. Larger studies will clarify ketamine’s optimal dosing, delivery route, and long-term safety, and for now ketamine remains on track to be the best alternative to ECT for severe depression, with a unique role in acutely suicidal ­patients.

 


podcastsTo learn more, listen to our 9/27/21 podcast, “The Spiritual Origins of Ketamine.” Search for “Carlat” on your podcast store.


General Psychiatry
KEYWORDS ect esketamine ketamine suicide treatment-resistant-depression
    Michael Posternak, MD.

    Psychological Benefits of Abstaining from Social Media

    More from this author
    www.thecarlatreport.com
    Issue Date: September 10, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Genetic Testing in Depression
    Desert Island Diagnoses
    Atomoxetine: Myths and Truths
    Overdiagnosis in Psychiatry
    Psilocybin vs Escitalopram for Depression
    Pilot Study of Ketamine vs ECT for Major Depression
    CME Post-Test - Overdiagnosis, TCPR, September 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.